These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. Katayama Y; Yamada T; Tanimura K; Yoshimura A; Takeda T; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K Thorac Cancer; 2019 Mar; 10(3):526-532. PubMed ID: 30666802 [TBL] [Abstract][Full Text] [Related]
43. Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer. La-Beck NM; Nguyen DT; Le AD; Alzghari SK; Trinh ST Pharmacotherapy; 2020 Mar; 40(3):239-255. PubMed ID: 31930528 [TBL] [Abstract][Full Text] [Related]
44. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Xia L; Liu Y; Wang Y Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829 [TBL] [Abstract][Full Text] [Related]
45. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition]. Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489 [TBL] [Abstract][Full Text] [Related]
46. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH Front Immunol; 2021; 12():654463. PubMed ID: 34054817 [TBL] [Abstract][Full Text] [Related]
47. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer. Lo Russo G; Facchinetti F; Tiseo M; Garassino MC; Ferrara R Curr Oncol Rep; 2020 Apr; 22(5):41. PubMed ID: 32296957 [TBL] [Abstract][Full Text] [Related]
48. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC. Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593 [TBL] [Abstract][Full Text] [Related]
49. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312 [TBL] [Abstract][Full Text] [Related]
50. [Application Progress of Immune Checkpoint Inhibitors in Oncogene-driven Advanced Non-small Cell Lung Cancer]. Zhang T; Li B Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):188-195. PubMed ID: 33819969 [TBL] [Abstract][Full Text] [Related]
51. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors. Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165 [TBL] [Abstract][Full Text] [Related]
52. First-line combination immunotherapy for metastatic non-small cell lung cancer. Chen YM J Chin Med Assoc; 2020 May; 83(5):433-441. PubMed ID: 32132380 [TBL] [Abstract][Full Text] [Related]
53. Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Nojima Y; Shimizu K; Saisho S; Maeda AI; Kurosaki T; Kurose K; Oga T; Oka M; Nakata M Anticancer Res; 2021 Nov; 41(11):5469-5475. PubMed ID: 34732416 [TBL] [Abstract][Full Text] [Related]
54. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653 [TBL] [Abstract][Full Text] [Related]
55. Zhu G; Shi R; Li Y; Zhang Z; Xu S; Chen C; Cao P; Zhang H; Liu M; Pan Z; Liu H; Chen J Front Immunol; 2021; 12():670040. PubMed ID: 34512623 [TBL] [Abstract][Full Text] [Related]
56. Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study). Takamori S; Ohba T; Shimokawa M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Seto T; Takenoyama M PLoS One; 2021; 16(10):e0258616. PubMed ID: 34679113 [TBL] [Abstract][Full Text] [Related]
57. Identification of Deleterious Zhang K; Hong X; Song Z; Xu Y; Li C; Wang G; Zhang Y; Zhao X; Zhao Z; Zhao J; Huang M; Huang D; Qi C; Gao C; Cai S; Gu F; Hu Y; Xu C; Wang W; Lou Z; Zhang Y; Liu L Clin Cancer Res; 2020 Jul; 26(14):3649-3661. PubMed ID: 32241817 [TBL] [Abstract][Full Text] [Related]
58. The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer. Duttagupta S; Hakozaki T; Routy B; Messaoudene M Curr Oncol; 2023 Oct; 30(11):9406-9427. PubMed ID: 37999101 [TBL] [Abstract][Full Text] [Related]
59. Effect of Concomitant Use of Analgesics on Prognosis in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Mao Z; Jia X; Jiang P; Wang Q; Zhang Y; Li Y; Fu X; Jiao M; Jiang L; Liu Z; Guo H Front Immunol; 2022; 13():861723. PubMed ID: 35603146 [TBL] [Abstract][Full Text] [Related]
60. Biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer. Fuschillo S; Battiloro C; Rocco D; D Gravara L; Motta A; Maniscalco M Biomark Med; 2020 Jul; 14(11):929-932. PubMed ID: 32940076 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]